In September 2014, the Federal government banned Apotex from importing products from its Indian facilities citing “significant concerns” about how research data was handled. The Federal court subsequently cancelled the ban and allowed Apotex to import from India. However, Health Canada put inspectors in Apotex’s Canadian facilities and retested any product from India before allowing them to be sold in Canada.
Apotex is currently suing the government for $500 million, claiming financial and reputational damage from the ban. Morneau sits on the cabinet committee on litigation management. While the $500-million claim has received most of the attention, Apotex’s suit includes another provision: they want a data-integrity requirement dropped for new drug applications, making it easier to sell drugs in Canada —potentially including those manufactured in India.
Nothing to see here. Move along.
No comments:
Post a Comment